Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Interest & Investment Income (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Interest & Investment Income data on record, last reported at $11.2 million in Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 22.36% year-over-year to $11.2 million; the TTM value through Dec 2025 reached $52.0 million, up 25.47%, while the annual FY2025 figure was $52.0 million, 25.47% up from the prior year.
  • Interest & Investment Income reached $11.2 million in Q4 2025 per CRNX's latest filing, down from $12.5 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $14.8 million in Q1 2025 and bottomed at $23000.0 in Q2 2021.
  • Average Interest & Investment Income over 5 years is $5.6 million, with a median of $2.3 million recorded in 2023.
  • Peak YoY movement for Interest & Investment Income: crashed 94.6% in 2021, then soared 6150.0% in 2022.
  • A 5-year view of Interest & Investment Income shows it stood at $80000.0 in 2021, then soared by 2280.0% to $1.9 million in 2022, then soared by 253.05% to $6.7 million in 2023, then soared by 113.75% to $14.4 million in 2024, then fell by 22.36% to $11.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $11.2 million in Q4 2025, $12.5 million in Q3 2025, and $13.5 million in Q2 2025.